Search research articles
Contact Us
Filters
Showing results (501-510 of 636) with videos related to
Page
of 64
Sort By:
Gastroenterology
|
July 12, 2020
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease
Sonja Lang, Münevver Demir, Anna Martin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 28, 2018
Discovery of Half-life of Circulating Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B Infection Using Heavy Water Labeling
Rohit Loomba, Martin Decaris, Kelvin W Li, et al.
Digestive Diseases (Basel, Switzerland)
|
May 26, 2023
Quality Assessment of Ultrasound and Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis
Jingxuan Quek, Darren Jun Hao Tan, Kai En Chan, et al.
Alimentary Pharmacology & Therapeutics
|
November 15, 2023
Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality
Sung Won Lee, Daniel Q Huang, Ricki Bettencourt, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 11, 2019
YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity
Lirui Wang, Magdalena Mazagova, Chuyue Pan, et al.
Journal of Hepatology
|
April 30, 2023
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography
Jia-Xu Liang, Javier Ampuero, Hao Niu, et al.
Lancet (London, England)
|
November 14, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
Mazen Noureddin, Stephen A Harrison, Rohit Loomba, et al.
Gastroenterology
|
July 31, 2018
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba, Zeid Kayali, Mazen Noureddin, et al.
Alimentary Pharmacology & Therapeutics
|
January 13, 2026
Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA)
Veeral Ajmera, Raj Vuppalanchi, Mandana Khalili, et al.
Egastroenterology
|
December 29, 2025
Metabolic dysfunction and alcohol-associated liver disease (MetALD)
Bin Gao, Juan Pablo Arab, Suthat Liangpunsakul, et al.
Page
of 64
Search research articles
Search
Showing results (501-510 of 636) with videos related to
Sort By:
Page
of 64
Gastroenterology
|
July 12, 2020
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease
Sonja Lang, Münevver Demir, Anna Martin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 28, 2018
Discovery of Half-life of Circulating Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B Infection Using Heavy Water Labeling
Rohit Loomba, Martin Decaris, Kelvin W Li, et al.
Digestive Diseases (Basel, Switzerland)
|
May 26, 2023
Quality Assessment of Ultrasound and Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis
Jingxuan Quek, Darren Jun Hao Tan, Kai En Chan, et al.
Alimentary Pharmacology & Therapeutics
|
November 15, 2023
Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality
Sung Won Lee, Daniel Q Huang, Ricki Bettencourt, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 11, 2019
YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity
Lirui Wang, Magdalena Mazagova, Chuyue Pan, et al.
Journal of Hepatology
|
April 30, 2023
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography
Jia-Xu Liang, Javier Ampuero, Hao Niu, et al.
Lancet (London, England)
|
November 14, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
Mazen Noureddin, Stephen A Harrison, Rohit Loomba, et al.
Gastroenterology
|
July 31, 2018
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba, Zeid Kayali, Mazen Noureddin, et al.
Alimentary Pharmacology & Therapeutics
|
January 13, 2026
Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA)
Veeral Ajmera, Raj Vuppalanchi, Mandana Khalili, et al.
Egastroenterology
|
December 29, 2025
Metabolic dysfunction and alcohol-associated liver disease (MetALD)
Bin Gao, Juan Pablo Arab, Suthat Liangpunsakul, et al.
Page
of 64